NASDAQ:VRAYViewray Stock Price, Forecast & News

Viewray's stock was trading at $1.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRAY stock has increased by 36.1% and is now trading at $2.30. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viewray.

Viewray is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Viewray.

Viewray Inc (NASDAQ:VRAY) released its quarterly earnings data on Thursday, April, 30th. The company reported ($0.19) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.19). The company earned $14.25 million during the quarter, compared to the consensus estimate of $12.47 million. Viewray had a negative net margin of 139.91% and a negative return on equity of 71.37%. View Viewray's earnings history.

10 analysts have issued 12-month price objectives for Viewray's shares. Their forecasts range from $2.00 to $8.00. On average, they anticipate Viewray's stock price to reach $4.83 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price. View analysts' price targets for Viewray.

News headlines about VRAY stock have been trending very negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Viewray earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Viewray.

Some companies that are related to Viewray include InMode (INMD), Zynex (ZYXI), Natus Medical (NTUS), BioLife Solutions (BLFS), TransMedics Group (TMDX), AxoGen (AXGN), Stereotaxis (STXS), Semler Scientific (SMLR), Cutera (CUTR), BioSig Technologies (BSGM), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), Fc Global Realty (FCRE) and electroCore (ECOR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Anavex Life Sciences (AVXL) and Inovio Pharmaceuticals (INO).

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRAY stock can currently be purchased for approximately $2.30.

Viewray has a market capitalization of $339.02 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

The official website for Viewray is www.viewray.com.

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]